Insulin-like growth factor receptor type I as a target for cancer therapy

Immunotherapy

Volumn 1, Issue 2, 2009, Pages 265-279

  Goestsch, Liliane ^a   Corvaïa, Nathalie ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antibody; Biomarker; Cancer; IGF IR; Translational research; Tyrosine kinase inhibitor

Indexed keywords

3 [3 (4 METHYLPIPERAZIN 1 YL)CYCLOBUTYL] 1 (2 PHENYLQUINOLIN 7 YL)IMIDAZOL[1,5 A]PYRAZIN 8 YLAMINE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; ADENOSINE TRIPHOSPHATE; AG 538; AMG 479; AXL 1717; BENZIMIDAZOLE DERIVATIVE; BIOLOGICAL MARKER; BMS 536924; BMS 554417; BVP 51004; CP 751871; CYCLOLIGNAN PICROPODOPHYLLIN; DEXAMETHASONE; ERLOTINIB; IMC A12; INSM 18; INSULIN RECEPTOR; MK 0646; MONOCLONAL ANTIBODY IGF IR; NORDIHYDROGUAIARETIC ACID; NVP AEW 541; OSI 906; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLO 5 CARBOXALDEHYDE DERIVATIVE; SOMATOMEDIN C RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIC ACID; XL 228;

ACUTE LYMPHOCYTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BINDING SITE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RELAPSE; CANCER THERAPY; CARCINOGENESIS; CHILL; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CYTOTOXICITY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; EWING SARCOMA; FATIGUE; FEVER; GROWTH INHIBITION; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERGLYCEMIA; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MUSCLE CRAMP; NAUSEA; NEUROECTODERM TUMOR; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PAIN; PANCREAS CANCER; PATIENT SELECTION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PURPURA; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SMALL CELL CARCINOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THRUSH; URIC ACID BLOOD LEVEL; VEIN THROMBOSIS; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG THERAPY; HUMANS; NEOPLASMS; PATIENT SELECTION; PROTEIN ENGINEERING; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN;

EID: 76649141789     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.2.265     Document Type: Review

References (128)

1. Ullrich A, Gray A, Tam AW et al.: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5(10), 2503-2512 (1986). ■ First paper reporting the cloning of type I insulin-like growth factor (IGF-IR) and the high homology between IGF-IR and insulin receptor.
2. Yakar S, Liu JL, Stannard B et al.: Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl Acad. Sci. USA 96(13), 7324-7329 (1999).
3. Schally AV, Varga JL, Engel JB: Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat. Clin. Pract. Endocrinol. Metab. 4(1), 33-43 (2008).
4. Marron-Terada PG, Brzycki-Wessell MA, Dahms NM: The two mannose 6-phosphate binding sites of the insulin-like growth factor-II/mannose 6-phosphate receptor display different ligand binding properties. J. Biol. Chem. 273(35), 22358-22366 (1998).
5. Osipo C, Dorman S, Frankfater A: Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors. Exp. Cell Res. 264(2), 388-396 (2001).
6. Soos MA, Siddle K: Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. Biochem. J. 263(2), 553-563 (1989). ■ One of the first papers reporting the existence of hybrid IGF-IR/insulin receptors.
7. TreadwayJL, Morrison BD, Goldfine ID, Pessin J E: Assembly of insulin/insulin-like growth factor-1 hybrid receptors in vitro. J. Biol. Chem. 264(36), 21450-21453 (1989).
8. Siddle K, Soos MA, Field CE, Nave BT: Hybrid and atypical insulin/insulin-like growth factor I receptors. Horm. Res. 41 (Suppl. 2), 56-64 (1994).
9. Denley A, Wallace JC, Cosgrove LJ, Forbes BE: The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm. Metab. Res. 35(11-12), 778-785 (2003).
10. Sciacca L, Prisco M, Wu A et al.: Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology 144(6), 2650-2658 (2003). (Pubitemid 36629918)
11. Frasca F, Pandini G, Scalia P et al.: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell Biol. 19(5), 3278-3288 (1999).
12. Soos MA, Field CE, Siddle K: Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem. J. 290(Pt 2), 419-426 (1993).
13. Frattali AL, Pessin JE: Relationship between alpha subunit ligand occupancy and β subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. J. Biol. Chem. 268(10), 7393-7400 (1993).
14. Belfiore A: The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr. Pharm. Des. 13(7), 671-686 (2007).
15. Kato H, Faria TN, Stannard B, Roberts CT Jr, LeRoith D: Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (αIR-3). J. Biol. Chem. 268(4), 2655-2661 (1993).
16. Favelyukis S, Till JH, Hubbard SR, Miller WT: Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Biol. 8(12), 1058-1063 (2001).
17. Kato H, Faria TN, Stannard B, Roberts CT Jr, LeRoith D: Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol. Endocrinol. 8(1), 40-50 (1994).
18. Navarro M, Baserga R: Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology 142(3), 1073-1081 (2001). (Pubitemid 32202816)
19. Samani AA, Yakar S, LeRoith D, Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28(1), 20-47 (2007).
20. Siddle K, Urso B, Niesler CA et al.: Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem. Soc. Trans. 29(Pt 4), 513-525 (2001).
21. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75(1), 59-72 (1993). ■ Paper that clearly demonstrated that IGF-IR is critical for normal growth and development.
22. Bateman JM, McNeill H: Insulin/IGF signalling in neurogenesis. Cell Mol. Life Sci. 63(15), 1701-1705 (2006).
23. Mathews LS, Hammer RE, Behringer RR et al.: Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123(6), 2827-2833 (1988).
24. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta. 1332(3), F105-F126 (1997). ■■ One of a series of outstanding reviews by the director of the laboratory that identified key roles of IGF-IR in transformation and protection from apoptosis.
25. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O: Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res. 59(15), 3588-3591 (1999). (Pubitemid 29381857)
26. Ouban A, Muraca P, Yeatman T, Coppola D: Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol. 34(8), 803-808 (2003).
27. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21(3), 215-244 (2000).
28. Hankinson SE, Willett WC, Colditz GA et al.: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113), 1393-1396 (1998).
29. Chan JM, Stampfer MJ, Giovannucci E et al.: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279(5350), 563-566 (1998).
30. Yu H, Spitz MR, Mistry J et al.: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl Cancer Inst. 91(2), 151-156 (1999). (Pubitemid 29042692)
31. Ma J, Pollak MN, Giovannucci E et al.: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl Cancer Inst. 91(7), 620-625 (1999). (Pubitemid 29194048)
32. Baserga R, Peruzzi F, Reiss K: The IGF-1 receptor in cancer biology. Int. J. Cancer 107(6), 873-877 (2003).
33. Sell C, Rubini M, Rubin R et al.: Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl Acad. Sci. USA 90(23), 11217-11221 (1993). ■ Along with [34], establishes the critical role of IGF-IR in cellular transformation.
34. Sell C, Dumenil G, Deveaud C et al.: Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell Biol. 14(6), 3604-3612 (1994). ■ Along with [33], establishes the critical role of IGF-IR in cellular transformation.
35. DiGiovanni J, Kiguchi K, Frijhoff A et al.: Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc. Natl. Acad. Sci. USA 97(7), 3455-3460 (2000).
36. Kulik G, Klippel A, Weber MJ: Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell Biol. 17(3), 1595-1606 (1997).
37. D'Ambrosio C, Valentinis B, Prisco M et al.: Protective effect of the insulin-like growth factor I receptor on apoptosis induced by okadaic acid. Cancer Res. 57(15), 3264-3271 (1997). (Pubitemid 27351745)
38. Wu Y, Tewari M, Cui S, Rubin R: Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J. Cell Physiol. 168(3), 499-509 (1996). (Pubitemid 26302856)
39. Harrington EA, Bennett MR, Fanidi A, Evan GI: c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J.. 13(14), 3286-3295 (1994). ■ Articles [39-42] are key papers showing that IGF-I protects against apoptosis.
40. Resnicoff M, Coppola D, Sell C et al.: Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 54(18), 4848-4850 (1994). ■ Articles [39-42] are key papers showing that IGF-I protects against apoptosis.
41. O'Connor R, Kauffmann-Zeh A, Liu Y et al.: Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell Biol. 17(1), 427-435 (1997). ■ Articles [39-42] are key papers showing that IGF-I protects against apoptosis.
42. Resnicoff M, Abraham D, Yutanawiboonchai W et al.: The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55(11), 2463-2469 (1995). ■ Articles [39-42] are key papers showing that IGF-I protects against apoptosis.
43. Lopez T,Hanahan D: Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 1(4), 339-353 (2002).
44. Hazan RB, Qiao R, Keren R, Badano I, Suyama K: Cadherin switch in tumor progression. Ann. NY Acad. Sci. 1014), 155-163 (2004).
45. Zhang D, Samani AA, Brodt P: The role of the IGF-I receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis. Horm. Metab. Res. 35(11-12), 802-808 (2003).
46. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D: A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J. Biol. Chem. 279(6), 5017-5024 (2004).
47. Dunn SE, Ehrlich M, Sharp NJ et al.: A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 58(15), 3353-3361 (1998).
48. Albanell J, Baselga J: Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl. Cancer Inst. 93(24), 1830-1832 (2001). ■ Along with [49], suggests that IGF-IR could be involved in trastuzumab resistance.
49. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 93(24), 1852-1857 (2001). ■ Along with [48], suggests that IGF-IR could be involved in trastuzumab resistance.
50. Guix M, Faber AC, Wang SE et al.: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118(7), 2609-2619 (2008). ■■ Link between acquired resistance to EGF receptor tyrosine kinase inhibitors (TKIs) and IGF-IR.
51. Goetsch L, Gonzalez A, Leger O et al.: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer. 113(2), 316-328 (2005).
52. Slomiany MG, Black LA, Kibbey MM, Day TA, Rosenzweig SA: IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem. Biophys. Res. Commun. 342(3), 851-858 (2006).
53. Jiang Y, Rom WN, Yie TA, Chi CX, Tchou-Wong KM: Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 18(44), 6071-6077 (1999). (Pubitemid 29535019)
54. Chernicky CL, Yi L, Tan H, Gan SU, Ilan J: Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther. 7(3), 384-395 (2000). (Pubitemid 30210405)
55. Resnicoff M: Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I receptor (review). Int. J. Mol. Med. 1(5), 883-888 (1998).
56. Andrews DW, Resnicoff M, Flanders AE et al.: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J. Clin. Oncol. 19(8), 2189-2200 (2001).
57. Arteaga CL,Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 49(22), 6237-6241 (1989). ■ First results showing the relevance of using antibodies to target IGF-IR.
58. Maloney EK, McLaughlin JL, Dagdigian NE et al.: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63(16), 5073-5083 (2003).
59. Hailey J, Maxwell E, Koukouras K et al.: Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol. Cancer Ther. 1(14), 1349-1353 (2002).
60. Zia F, Jacobs S, Kull F Jr et al.: Monoclonal antibody αIR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J. Cell Biochem. Suppl. 24, 269-275 (1996).
61. Yin D, Vreeland F, Schaaf LJ et al.: Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin. Cancer Res. 13(3), 1000-1009 (2007).
62. Durai R, Yang SY, Sales KM et al.: Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer. Colorectal Dis. 9(7), 625-631 (2007). (Pubitemid 47261828)
63. Garber K: IGF-1: old growth factor shines as new drug target. J. Natl Cancer Inst. 97(11), 790-792 (2005).
64. De Meyts P,Whittaker J: Structural biology of insulin and IGF1 receptors: implications for drug design. Nat. Rev. Drug Discov. 1(10), 769-783 (2002).
65. Garcia-Echeverria C, Pearson MA, Marti A et al.: In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5(3), 231-239 (2004). ■ First TKI targeting IGF-IR described for its in vivo antitumor effect.
66. Mitsiades CS, Mitsiades NS, McMullan CJ et al.: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5(3), 221-230 (2004).
67. Warshamana-Greene GS, Litz J, Buchdunger E et al.: The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol. Cancer Ther. 3(5), 527-535 (2004).
68. Scotlandi K, Manara MC, Nicoletti G et al.: Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65(9), 3868-3876 (2005).
69. Bell IM, Stirdivant SM, Ahern J et al.: Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases. Biochemistry 44(27), 9430-9440 (2005). (Pubitemid 40962041)
70. Haluska P, Carboni JM, Loegering DA et al.: In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res. 66(1), 362-371 (2006).
71. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M et al.: A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol. Cancer Ther. 6(8), 2158-2167 (2007).
72. Ji QS, Mulvihill M, Rosenfeld-Franklin M et al.: Preclinical characterization of OSI-906: a novel IGF-1R kinase inhibitor in clinical trials. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstract C192).
73. Blum G, Gazit A, Levitzki A: Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J. Biol. Chem. 278(42), 40442-40454 (2003). ■ Along with [74], describes new classes of IGF-IR TKI that do not interfere with insulin receptors.
74. Stromberg T, Ekman S, Girnita L et al.: IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107(2), 669-678 (2006). ■ Along with [73], describes new classes of IGF-IR TKI that do not interfere with insulin receptors.
75. Girnita A, Ali-Ericsson C, Economou MA et al.: The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin. Cancer Res. 12(4), 1383-1391 (2006).
76. Girnita A, Girnita L, del Prete F et al.: Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64(1), 236-242 (2004). (Pubitemid 38114104)
77. Vasilcanu R, Vasilcanu D, Rosengren L et al.: Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor potential mechanistic involvement of Mdm2 and β-arrestinl. Oncogene 27(11), 1629-1638 (2008).
78. Linder S, Shoshan MC, Gupta RS: Picropodophyllotoxin or podophyllotoxin does not induce cell death via insulin-like growth factor-I receptor. Cancer Res. 67(6), 2899-2900 (2007).
79. Larsson O,Axelson M: Cyclolignans as inhibitors of the insulin-like growth factor-I receptor. Cancer Res. 67(6), 2899 (2007).
80. Rosengren L, Vasilcanu D, Vasilcanu R et al.: IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R). Biochem. Biophys. Res. Commun. 347(4), 1059-1066 (2006).
81. Youngren JF, Gable K, Penaranda C et al.: Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res. Treat. 94(1), 37-46 (2005).
82. Noronha G, Cao J, Chow CP et al.: Inhibitors of ABL and the ABL-T315I mutation. Curr. Top. Med. Chem. 8(10), 905-921 (2008).
83. Britten C, Smith DC, Bui LA, Clary DO, Hurwitz HI: 390 POSTERA Phase I dose-escalation study of XL228, a potent IGF1R/Src inhibitor, in patients with advanced malignancies. Eur. J. Cancer Suppl. 6(12), 122-122 (2008).
84. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D: Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res. 66(4), 2391-2402 (2006). ■■ Articles [84-89] are a series of papers showing the efficacy of humanized or human antibodies neutralizing the IGF-IR.
85. Burtrum D, Zhu Z, Lu D et al.: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63(24), 8912-8921 (2003). ■■ Articles [84-89] are a series of papers showing the efficacy of humanized or human antibodies neutralizing the IGF-IR. (Pubitemid 38064071)
86. Schnitzer T, Kuenkele KP, Rebers F et al.: Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Eur. J. Cancer Suppl. 4(12), 66-67 (2006). ■■ Articles [84-89] are a series of papers showing the efficacy of humanized or human antibodies neutralizing the IGF-IR.
87. Beltran PJ, Mitchell P, Moody G, Lu J, Chung Y, Zhang X, Freeman D, Kendall RL, Calzone,FJ, and Radinsky,R. AMG-479, a fully human anti IGF-1 receptor antibody, inhibits PI3K/Akt signaling and exerts potent antitumor effects in combination with EGF-R inhibitors in pancreatic xenograft models. Presented at: 2007 Gastrointestinal Cancers Symposium. Orlando, Fl, USA, 19-21 January (2007). ■■ Articles [84-89] are a series of papers showing the efficacy of humanized or human antibodies neutralizing the IGF-IR.
88. Wang Y, Hailey J, Williams D et al.: Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol. Cancer Ther. 4(8), 1214-1221 (2005). ■■ Articles [84-89] are a series of papers showing the efficacy of humanized or human antibodies neutralizing the IGF-IR.
89. Loo D, Pryer N, Young P et al: The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol. Cancer Ther. 6(3), 856-865 (2007). ■■ Articles [84-89] are a series of papers showing the efficacy of humanized or human antibodies neutralizing the IGF-IR.
90. Cohen BD, Baker DA, Soderstrom C et al.: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11(5), 2063-2073 (2005).
91. Hariharan K, Dong J, Demarest S et al.: BIIB022, a fully human nonglycosylated γ4P antibody targeting IGF-1R for cancer therapy. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstract B210).
92. Kurmasheva R, Boltz C, Phelps D, Morton C, Houghton P: Combination of CP-751871, a human monoclonal antibody against the IGF-1 receptor, with rapamycin results in a highly effective therapy for xenografts derived from childhood sarcomas. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstract C172).
93. Cao L, Yu Y, Darko I et al.: Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 68(19), 8039-8048 (2008).
94. Allen GW, Saba C, Armstrong EA et al.: Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res. 67(3), 1155-1162 (2007). (Pubitemid 46270773)
95. Wurch T, Pandini G, Akla B et al.: In vitro and in vivo inhibition of functional responses at insulin-like growth factor-1/insulin hybrid receptors by h7C10, a novel humanized anti-IGF-1R monoclonal antibody. Eur. J. Cancer Suppl. 4(12), 61-61 (2006) (Poster 195).
96. Haluska P, Shaw HM, Batzel GN et al.: Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 13(19), 5834-5840 (2007).
97. Pollak M, Eisenberg P, Karp D et al.: Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Program and Abstracts of the AACR Meeting 2007, 3 Molecular Targets Meeting. Los Angeles, CA, USA, 14-18 April (2007) (Abstract LB-343).
98. Olmos D, Molife R, Okuno S et al.: Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstract A63).
99. Postel-Vinay S, Okuno S, Schuetze S et al.: 388 POSTER Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. Eur. J. Cancer Suppl. 6(12), 122-122 (2008).
100. Lacy MQ, Alsina M, Fonseca R et al.: Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J. Clin. Oncol. 26(19), 3196-3203 (2008).
101. Broussas M, Dupont J, Gonzalez A et al.: Molecular mechanisms involved in activity of h7C10, a humanised monoclonal antibody to IGF-1 receptor. Int. J. Cancer. (2008) (Epub ahead of print).
102. Atzori F, Tabernero J, Cervantes A et al.: A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGFlR) monoclonal antibody (mAb) in patients (pts) with advanced solid tumors. ASCO Meeting Abstracts. 26(Suppl. 15), 3519 (2008).
103. Leong S, Gore L, Benjamin R et al.: A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstratc A78).
104. Seraj J, Tsai M, Seiberling M, Cutler D: Evaluation of safety and pharmacokinetics of a fully human IGF-1 receptor antibody, SCH 717454, in healthy volunteers. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstract A72).
105. Higano C, LoRusso P, Gordon M et al.: A Phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstract B19).
106. Rothenberg M, Poplin E, Sandler A et al.: Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (mAb) IMC-A12, administered every other week to patients with advanced solid tumors. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstract C84).
107. Rodon J, Patnaik A, Stein M et al.: A Phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstract A77).
108. Tolcher AW, Rothenberg ML, Rodon J et al.: A Phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. ASCO Meeting Abstracts. 25 (Suppl. 18), 3002 (2007).
109. Moody G, Mitchell P, Cajulis E et al.: AMG 479, a fully human anti IGF-1 receptor monoclonal antibody, is efficacious against Ewing's sarcoma and osteosarcoma xenografts. Program and Abstracts of the AACR Molecular Targets and Cancer Therapeutics Meeting 2007. San Francisco, CA, USA, 22-26 October (2007) (Abstract A64).
110. Scotlandi K, Benini S, Nanni P et al.: Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 58(18), 4127-4131 (1998). ■ One of a series of papers showing that Ewing's sarcoma is highly sensitive to IGF-IR-targeted therapy.
111. Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer. 7(3), 169-181 (2007).
112. Karapetis CS, Khambata-Ford S, Jonker DJ et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl. J. Med. 359(17), 1757-1765 (2008).
113. Linardou H, Dahabreh IJ, Kanaloupiti D et al.: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. (2008).
114. Milano G, Etienne-Grimaldi MC, Dahan L et al.: Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann. Oncol. 19(12), 2033-2038 (2008).
115. Pandini G, Wurch T, Akla B et al.: Functional responses and in vivo antitumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur. J. Cancer 43(8), 1318-1327 (2007).
116. Haluska P, Carboni JM, TenEyck C et al.: HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 7(9), 2589-2598 (2008).
117. Hollier BG, Kricker JA, Van Lonkhuyzen DR, Leavesley DI, Upton Z: Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-kinase/AKT pathway by αv-integrins and the IGF-I receptor. Endocrinology 149(3), 1075-1090 (2008).
118. Canonici A, Steelant W, Rigot V et al.: Insulin-like growth factor-I receptor, E-cadherin and αv integrin form a dynamic complex under the control of α-catenin. Int. J. Cancer 122(3), 572-582 (2008). ■ Along with [119], first papers suggesting insulin receptor substrate (IRS-I) as a biomarker.
119. Byron SA, Horwitz KB, Richer JK et al.: Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br. J. Cancer 95(9), 1220-1228 (2006). ■ Along with [118], first papers suggesting IRS-I as a biomarker.
120. Baserga R: The insulin receptor substrate-1: a biomarker for cancer? Exp. Cell Res. DOI: 10.1016/j.yexcr.2008.09.017 (2008) (Epub ahead of print).
121. Deevi D, Burtrum D, Melchior M et al.: 516 POSTER Efficacy of EGFR and IGF-1R antibody therapy is independent of PTEN status in a selection of tumor models. Eur. J. Cancer Suppl. 6(12), 164-164 (2008).
122. Deevi D, Huiling L, Ludwig DL et al: Correlation analysis utilizing measurements of tumor biomarkers and antibody efficacy against EGFR, IGF1R and VEGFR2 receptors in multiple tumor models. Eur. J. Cancer Suppl. 6(12), 30-30 (2008).
123. Pitts TM, Kaufman SA, Tender JJ et al.: Development and characterization of predictive markers to the IGF-1R inhibitor, PQIP, in colorectal cancer (CRC). Eur. J. Cancer Suppl. 6(12), 31-31 (2008).
124. Sachdev D, Li SL, Hartell JS et al.: A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 63(3), 627-635 (2003). (Pubitemid 36158140)
125. Wu JD, Odman A, Higgins LM et al.: In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin. Cancer Res. 11(8), 3065-3074 (2005).
126. Lee SH, Li C, Zha J et al.: Understanding pharmacokinetics and pharmacodynamics relationship of anti-IGF1R antibody in vivo. Pregoram and Abstratcs of the AACR Annual Meeting, 2008. San Diego, CA, USA, 12-16 April (2008) (Abstract 3017). ■ Modulation of genes after inhibition of the IGF-IR pathway reported.
127. de Bono JS, Attard G, Adjei A et al.: Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin. Cancer Res. 13(12), 3611-3616 (2007).
128. ClinicalTrials.gov: a service of the US NIH. http://clinicaltrials.gov